Giving patients rosuvastatin before surgery does not prevent complications, study findsBMJ 2016; 353 doi: https://doi.org/10.1136/bmj.i2571 (Published 06 May 2016) Cite this as: BMJ 2016;353:i2571
- Susan Mayor
Perioperative rosuvastatin does not prevent postoperative atrial fibrillation or perioperative myocardial damage in patients undergoing elective cardiac surgery and is associated with an increased risk of acute kidney injury, a large randomised study published in the New England Journal of Medicine has shown.1
Researchers randomly assigned 1922 adult patients in sinus rhythm who were scheduled to undergo elective cardiac surgery with either coronary artery bypass grafting or surgical aortic valve replacement, or both, to perioperative rosuvastatin (20 mg daily) or placebo. Patients …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial